The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease
Open accessAbstract
Recent studies indicate that oxysterols, which are ligands for the nuclear hormone liver X receptors (LXR), decrease amyloid beta (Abeta) secretion in vitro. The effect was attributed primarily to the ATP-binding cassette transporter A1 (ABCA1) transcriptionally up-regulated by ligand-activated LXRs. We now examined the effect of the synthetic LXR ligand T0901317, which can be used in vivo, on Abeta production in vitro and in APP23 transgenic mice. T0901317 applied to a variety of in vitro models, including immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons caused a concentration-dependent decrease in Abeta secretion, and this effect was increased by the addition of apolipoprotein A-I. The inhibition of Abeta production by T0901317 was cell-type specific, being more prominent in primary neurons than in non-neuronal cells. Tangier fibroblasts lacking a functional ABCA1 secreted more Abeta than control fibroblasts, thus demonstrating the role of ABCA1 in amyloid precursor protein (APP) processing and Abeta generation. T0901317 treatment of 11-week-old APP23 mice for 6 days showed a significant increase in ABCA1 expression and a decrease in the ratio of soluble APP (sAPP)beta- to sAPPalpha-cleavage products. Most importantly, the treatment caused a statistically significant reduction in the levels of soluble Abeta40 and of Abeta42 in the brain these mice. Our experiments demonstrate that T0901317 decreases amyloidogenic processing of APP in vitro and in vivo, thus supporting the search for potent and specific LXR ligands with properties allowing therapeutic application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“dosing of APP transgenic mice with LXR agonists, which increase murine CNS apoE levels, also decrease A levels (Koldamova et al., 2005;Burns et al., 2006;Riddell et al., 2007).”
From Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels (2008) · cites this paper as Koldamova et al., 2005
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonist treatment alleviates AD-like pathology in mouse models of amyloidosis, possibly by inducing Abca1 expression (29, 43–48).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Koldamova et al. and Sun et al. reported that ABCA1 induction decreases Aβ levels in cells by inhibiting both β- and γ-cleavage of APP [62-64].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ABCA1 gene ablation in mice decreased APOE lipidation and levels and increased Aβ accumulation in APP transgenic mouse models.”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LXR agonists have been shown to decrease A deposition in the brain while modestly increasing apoE expression (Koldamova et al., 2005;Zelcer et al., 2007;Fitz et al., 2010).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Koldamova et al., 2005
Experimental — accuracy not yet measured
In the citing paper
“Interestingly, several genes expressed in the liver including liver X receptors (LXRs) have been suggested as potential therapeutic targets for AD [189–191].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationRole of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics · doi:10.1038/11921 · Cited by 1,433
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J. A., Medina, J. C., Li, L., Lustig, K. D., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,303
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis
Repa, J. J., & Mangelsdorf, D. J. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.459 · Cited by 762
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R. O., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 679
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Kivipelto, M., Helkala, E., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 642
Isoform-specific binding of apolipoprotein E to beta-amyloid.
LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., & Frail, D. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31529-6 · Cited by 540
Refolo, L. M., Pappolla, M. A., LaFrancois, J. J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M. H., Petanceska, S. S., et al. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0422 · Cited by 530
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Perez, R. G., Soriano, S., Hayes, J. D., Ostaszewski, B. L., Xia, W., Selkoe, D. J., Chen, X., Stokin, G. B., & Koo, E. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.18851 · Cited by 387
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., & Wellington, C. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407962200 · Cited by 385
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349
Liver X receptors in the central nervous system: From lipid homeostasis to neuronal degeneration
Wang, L., Schuster, G. U., Hultenby, K. R., Zhang, Q., Andersson, S., & Gustafsson, J.-Α. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172510899 · Cited by 298
Clee, S. M., Zwinderman, A. H., Engert, J. C., van Spaendonck‐Zwarts, K. Y., Molhuizen, H. O. F., Roomp, K., Jukema, J. W., van Wijland, M. J. A., van Dam, M., Hudson, T. J., et al. (2001) · Circulation · doi:10.1161/01.cir.103.9.1198 · Cited by 291
Differential Expression of Cholesterol Hydroxylases in Alzheimer's Disease
Brown, J. A., Theisler, C. M., Silberman, S., Magnuson, D. J., Gottardi-Littell, N. R., Lee, J. M., Yager, D., Crowley, J., Sambamurti, K., Rahman, M. M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402324200 · Cited by 281
Merched, A. J., Xia, Y., Visvikis‐Siest, S., Sérot, J., & Siest, G. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00103-7 · Cited by 279
Cholesterol and the Biology of Alzheimer's Disease
Wolozin, B. (2004) · Neuron · doi:10.1016/s0896-6273(03)00840-7 · Cited by 275
Oram, J. (2000) · Biochimica et Biophysica Acta · doi:10.1016/s1388-1981(00)00157-8 · Cited by 243
Elevated Low-Density Lipoprotein in Alzheimer's Disease Correlates with Brain Aβ 1–42 Levels
Kuo, Y.-M., Emmerling, M. R., Bisgaier, C. L., Essenburg, A. D., Lampert, H. C., Drumm, D., & Roher, A. E. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9652 · Cited by 238
Koldamova, R. P., Lefterov, I. M., Ikonomovic, M. D., Skoko, J., Lefterov, P. I., Isanski, B. A., DeKosky, S. T., & Lazo, J. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300044200 · Cited by 237
Self-citationRegulation of Cholesterol Homeostasis by the Liver X Receptors in the Central Nervous System
Whitney, K. D., Watson, M. A., Collins, J. L., Benson, W. G., Stone, T. M., Numerick, M. J., Tippin, T. K., Wilson, J. G., Winegar, D. A., & Kliewer, S. A. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.6.0835 · Cited by 211
Crosstalk between Rap1 and Rac regulates secretion of sAPPα
Maillet, M., Robert, S. J., Cacquevel, M., Gastineau, M., Vivien, D., Bertoglio, J. H., Zugaza, J. L., Fischmeister, R., & Lezoualc’h, F. (2003) · Nature Cell Biology · doi:10.1038/ncb1007 · Cited by 187
Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice
Shie, F.-S., Jin, L.-W., Cook, D. G., Leverenz, J. B., & LeBoeuf, R. C. (2002) · Neuroreport · doi:10.1097/00001756-200203250-00019 · Cited by 184
Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion
Sun, Y., Yao, J., Kim, T.-W., & Tall, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300760200 · Cited by 179
Laffitte, B. A., Joseph, S. B., Chen, M., Castrillo, A., Repa, J. J., Wilpitz, D. C., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2182-2191.2003 · Cited by 164
Liang, Y., Lin, S., Beyer, T. P., Zhang, Y., Wu, X., Bales, K. R., DeMattos, R. B., May, P. C., Li, S. D., Jiang, X., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02183.x · Cited by 160
ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease
Wollmer, M. A. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00094-5 · Cited by 147
Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid β
Zloković, B. V., Martel, C. L., Mačkić, J. B., Matsubara, E., Wısnıewskı, T., McComb, J. G., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2825 · Cited by 133
Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131
Self-citationKatzov, H., Chalmers, K. A., Palmgren, J., Andreasen, N., Johansson, B. E. A., Cairns, N. J., Gatz, M., Wilcock, G. K., Love, S., Pedersen, N. L., et al. (2004) · Human Mutation · doi:10.1002/humu.20012 · Cited by 128
Expression of human β‐secretase in the mouse brain increases the steady‐state level of β‐amyloid
Bodendorf, U., Danner, S., Fischer, F., Stefani, M., Sturchler, C., Wiederhold, K., Staufenbiel, M., & Paganetti, P. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00770.x · Cited by 123
Self-citationBonarek, M., Barberger‐Gateau, P., Letenneur, L., Deschamps, V., Iron, A., Dubroca, B., & Dartigues, J. (2000) · Neuroepidemiology · doi:10.1159/000026249 · Cited by 114
Koudinov, A. R., Berezov, T. T., Kumar, A. R., & Koudinova, N. V. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(97)00207-6 · Cited by 102
George, A. J., Holsinger, R. M. D., McLean, C., Laughton, K. M., Beyreuther, K. T., Evin, G. M., Masters, C. L., & Li, Q. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.009 · Cited by 83
Elevated Serum Total and LDL Cholesterol in Very Old Patients with Alzheimer’s Disease
Lesser, G. T., Kandiah, K., Libow, L. S., Likourezos, A., Breuer, B., Marin, D. B., Mohs, R. C., Haroutunian, V. H., & Neufeld, R. R. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051248 · Cited by 80
High Density Lipoprotein Inhibits Assembly of Amyloid β-Peptides into Fibrils
Olesen, O. F., & Dagø, L. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2372 · Cited by 76
Association of ABCA1 with late-onset Alzheimer’s disease is not observed in a case-control study
Li, Y., Tacey, K. M., Doil, L. M., van Luchene, R., Garcia, V., Rowland, C. M., Schrodi, S. J., Leong, D. U., Lau, K. F., Catanese, J., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.047 · Cited by 62
Human bleomycin hydrolase regulates the secretion of amyloid precursor protein
Lefterov, I. M., Koldamova, R. P., & Lazo, J. S. (2000) · The FASEB Journal · doi:10.1096/fj.99-0938com · Cited by 44
Self-citationProlonged biologically active transgene expression driven by HSV LAP2 in brain in vivo
Puskovic, V., Wolfe, D. P., Goss, J. R., Huang, S., Mata, M. M., Glorioso, J. C., & Fink, D. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.004 · Cited by 44
Self-citationHigh-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis
Kawashiri, M., Maugeais, C., & Rader, D. J. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0074-4 · Cited by 39
Utech, M., Höbbel, G., Rust, S., Reinecke, H., Assmann, G., & Walter, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4061 · Cited by 34
Self-citationHigh density lipoprotein decreases β-amyloid toxicity in cortical cell culture
Farhangrazi, Z. S., Ying, H. S.-C., Bu, G., Dugan, L. L., Fagan, A. M., Choi, D. W., & Holtzman, D. M. (1997) · Neuroreport · doi:10.1097/00001756-199703240-00013 · Cited by 28
Walter, M., Forsyth, N. R., Wright, W. E., Shay, J. W., & Roth, M. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401714200 · Cited by 19
Self-citationCysteine 73 in Bleomycin Hydrolase Is Critical for Amyloid Precursor Protein Processing
Lefterov, I. M., Koldamova, R. P., Lefterova, M. I., Schwartz, D. R., & Lazo, J. S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4860 · Cited by 19
Self-citationCharacterization of atherosclerosis in a patient with familial high-density lipoprotein deficiency
Walter, M., Kerber, S., Fechtrup, C., Seedorf, U., Breithardt, G., & Assmann, G. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90205-4 · Cited by 13
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 827
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782
Metadata
- Authors
- Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S.
- Affiliations
- University of Pittsburgh (US)
- Novartis Institutes for BioMedical Research (CH)
- University of Münster (DE)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Koldamova, Radosveta P.
- Lefterov, Iliya M.
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 6
- Pages
- 4079-4088
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1996457468
- Cited by
- 279
- References
- 55
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 17 · 2013: 22 · 2012: 15
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health
- National Institute on Aging (AG 18558, AG 23304, R03AG023304)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- liver X receptor, T0901317, amyloid-beta, Alzheimer's disease, ABCA1, oxysterols, APP processing, APP23 transgenic mice, apolipoprotein A-I, soluble APP alpha, cell type specificity, LXR ligands
- MeSH terms
- Liver X Receptors, Benzenesulfonamides, Alzheimer Disease, Animals, Anticholesteremic Agents, Brain, Cloning, Molecular, Disease Models, Animal, DNA-Binding Proteins, Enzyme-Linked Immunosorbent Assay, Fibroblasts, Fluorocarbons, Humans, Hydrocarbons, Fluorinated, Ligands, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Protein Binding, Sulfonamides, Time Factors, Transcription, Genetic, Transfection, Blotting, Western, Up-Regulation, Amyloid beta-Protein Precursor, Apolipoprotein A-I, DNA, Complementary, Simplexvirus, Receptors, Cytoplasmic and Nuclear, Immunoprecipitation, Mice, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
